Paper Details

  1. Home
  2. Paper Details

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

Author: , EsakiMotohiro, HibiToshifumi, HisamatsuTadakazu, IshidaTetsuya, KanaiTakanori, KatoShingo, MatsuiToshiyuki, MatsumotoTakayuki, MotoyaSatoshi, NagahoriMasakazu, NaitoYuji, NakagawaTomoo, NakaseHiroshi, NojimaMasanori, SuzukiYasuo, WatanabeKenji, WatanabeMamoru, YoshimuraNaoki

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This open-labelled prospective study found that the clinical efficacy of a combination of adalimumab and azathioprine at week 26 did not differ from that of adalimumab monotherapy in patients with Crohn's disease naïve to both medications. However, the rate of endoscopic improvement at week 26 was significantly higher in the combination group.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: The efficacy of azathioprine for Crohn's disease under adalimumab treatment remains obscure. METHODS: In an open-labelled prospective study, we evaluated the efficacy of adalimumab with and without azathioprine in patients with active Crohn's disease, who were naïve to biologic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/ecco-jcc/jjw152

データ提供：米国国立医学図書館（NLM）

Adalimumab Monotherapy versus Combination Therapy for Crohn's Disease

This study compares the effectiveness of adalimumab monotherapy versus a combination of adalimumab and azathioprine in treating Crohn's disease. It's like comparing two different caravan routes through the desert, each with its own advantages and disadvantages! The study found that while the combination therapy did not lead to significantly better clinical remission rates at week 26, it showed a greater improvement in endoscopic severity.

Adalimumab and Azathioprine: Exploring the Optimal Treatment Strategy

The study found that while adalimumab monotherapy and combination therapy with azathioprine did not show significant differences in clinical remission rates, the combination therapy led to greater improvement in endoscopic severity. This suggests that the combination therapy might be more effective in reducing inflammation in the intestines, but further research is needed to confirm this. It's like finding two different oases in the desert, each offering unique benefits, and needing to choose the best route based on your specific needs.

Optimizing Crohn's Disease Treatment: A Multifaceted Approach

This research emphasizes the need for a multifaceted approach to treating Crohn's disease, taking into account the individual needs of each patient. The study's findings suggest that while adalimumab monotherapy can be effective, combining it with azathioprine may offer additional benefits. It's like navigating the desert with a combination of tools and strategies, adapting to the changing landscape and optimizing your journey for success.

Dr. Camel's Conclusion

This study offers valuable insights into the comparative effectiveness of adalimumab monotherapy and combination therapy for Crohn's disease. It's like choosing the best caravan route through the desert, considering factors such as speed, safety, and resources. The study's findings highlight the importance of personalized treatment plans and the need for ongoing research to identify the optimal strategies for managing this complex condition.

Date :
  1. Date Completed 2017-05-22
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

27566367

DOI: Digital Object Identifier

10.1093/ecco-jcc/jjw152

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.